ConductScience.org, home

Paper39799396

Characterization of a novel conditional knockout mouse model to assess efficacy of mRNA therapy in the context of severe OTC deficiency.

Zhou J and 13 others. Mol Ther, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Characterization of a novel conditional knockout mouse model to assess efficacy of mRNA therapy in the context of severe OTC deficiency. Papers, record 39799396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39799396

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Characterization of a novel conditional knockout mouse model to assess efficacy of mRNA therapy in the context of severe OTC deficiency.
PubMed
Journal
Mol Ther
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-10-08
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou JJenny
2Liang SShi
3Yin LLing
4Frassetto AAndrea
5Graham ARAnne-Renee
6White RRebecca
7Principe MMaria
8Severson MMadelyn
9Palmer TTiffany
10Naidu SShan
11Jacquinet EEric
12Zimmer MMike
13Finn PFPatrick F
14Martini PGVPaolo G V

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
RNA, MessengerMajor topic
Ornithine Carbamoyltransferase Deficiency DiseaseMajor topic
Ornithine CarbamoyltransferaseMajor topic
Genetic TherapyMajor topic
Animals
Mice
Disease Models, Animal
Mice, Knockout
Nanoparticles
Humans
Tamoxifen

Source PubMed

Download CSV of topics

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125647322A new mouse model of mild ornithine transcarbamylase deficiency (spf-j) displays cerebral amino acid perturbations at baseline and upon systemic immune activation.PLoS One2015https://conductscience.org/library/papers/25647322PubMed
235211641Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression.Mol Ther Methods Clin Dev2022https://conductscience.org/library/papers/35211641PubMed
39686344The biochemical and molecular spectrum of ornithine transcarbamylase deficiency.J Inherit Metab Dis1998https://conductscience.org/library/papers/9686344PubMed
429653760A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates.Mol Ther2018https://conductscience.org/library/papers/29653760PubMed
528283349AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.Mol Genet Metab2017https://conductscience.org/library/papers/28283349PubMed
618562231Cross-sectional multicenter study of patients with urea cycle disorders in the United States.Mol Genet Metab2008https://conductscience.org/library/papers/18562231PubMed
715050978The role of liver transplantation in urea cycle disorders.Mol Genet Metab2004https://conductscience.org/library/papers/15050978PubMed
827860485
An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease.
Expert Opin Drug Metab Toxicol2017https://conductscience.org/library/papers/27860485PubMed
929511548Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis.United European Gastroenterol J2018https://conductscience.org/library/papers/29511548PubMed
1022642880Suggested guidelines for the diagnosis and management of urea cycle disorders.Orphanet J Rare Dis2012https://conductscience.org/library/papers/22642880PubMed
11481951Ornithine transcarbamylase deficiency in mutant mice I. Studies on the characterization of enzyme defect and suitability as animal model of human disease.Pediatr Res1979https://conductscience.org/library/papers/481951PubMed
1216237708Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University.Liver Transpl2005https://conductscience.org/library/papers/16237708PubMed
133162766Correction of mouse ornithine transcarbamylase deficiency by gene transfer into the germ line.Nucleic Acids Res1988https://conductscience.org/library/papers/3162766PubMed
1433473356Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector.Mol Ther Methods Clin Dev2021https://conductscience.org/library/papers/33473356PubMed
1529433939Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency.Mol Ther2018https://conductscience.org/library/papers/29433939PubMed
1626059767Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update.J Genet Genomics2015https://conductscience.org/library/papers/26059767PubMed
1723430554Amino Acid Profiles in Patients with Urea Cycle Disorders at Admission to Hospital due to Metabolic Decompensation.JIMD Rep2013https://conductscience.org/library/papers/23430554PubMed
1811124797Ornithine carbamoyltransferase deficiency.Arch Dis Child2001https://conductscience.org/library/papers/11124797PubMed
1921376697Paediatric liver transplantation for metabolic disorders. Part 1: Liver-based metabolic disorders without liver lesions.Clin Res Hepatol Gastroenterol2011https://conductscience.org/library/papers/21376697PubMed
2021376696Paediatric liver transplantation for metabolic disorders. Part 2: Metabolic disorders with liver lesions.Clin Res Hepatol Gastroenterol2011https://conductscience.org/library/papers/21376696PubMed

See all 38 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42398834New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.J Control Release2026https://conductscience.org/library/papers/42398834PubMed
40976841Current Treatment Modalities for Urea Cycle Disorders.Paediatr Drugs2025https://conductscience.org/library/papers/40976841PubMed
39986270mRNA therapy as primary and bridge therapy for inborn errors of metabolism.Mol Ther2025https://conductscience.org/library/papers/39986270PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39799396

GET https://conductscience.org/api/papers/v1/39799396/references?page=2